title: Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma.
abstract: Interleukin 12 (IL-12) is known to play an important role in the development of an antitumor response. Its activity has been shown to be dependent upon the intermediate production of IFN-gamma and the influx into the tumor of CD8 lymphocytes. In a murine model, tumor regression induced by IL-12 treatment correlated with IFN-gamma, IP-10, and Mig expression in the tumor bed and was abrogated by antibodies to both chemokines. Here we examined the effects of rHuIL-12 on IFN-gamma and CXC chemokine gene expression in patients with renal cell carcinoma (RCC) in an attempt to determine whether a similar series of molecular events leading to IL-12-mediated tumor regression in mice is also detectable in humans. As in the murine RENCA model, cultured RCC cells themselves could be induced by IFN-gamma to synthesize IP-10 and Mig mRNA. Explanted RCC produced IFN-gamma and IP-10 mRNA in response to IL-12 treatment, which was consistent with the finding that biopsied RCC tumors from IL-12-treated patients also variably expressed augmented levels of those molecules after therapy. Although Mig mRNA was present in the majority of biopsied tumors prior to treatment, both the Mig and IP-10 chemokines as well as IFN-gamma were induced in the peripheral blood mononuclear cells of IL-12-treated patients. Skin biopsies of IL-12-treated patients also all synthesized IP-10 mRNA. This study demonstrates that recombinant human IL-12 therapy of patients with RCC has the potential to induce the expression of gene products within the tumor bed that may contribute to the development of a successful antitumor response.
authors.affiliation: Department of Hematology, The Cleveland Clinic Foundation, Ohio 44195, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Bukowski
authors.forename: P
authors.initials: P
authors.lastname: Rayman
authors.forename: L
authors.initials: L
authors.lastname: Molto
authors.forename: C S
authors.initials: CS
authors.lastname: Tannenbaum
authors.forename: T
authors.initials: T
authors.lastname: Olencki
authors.forename: D
authors.initials: D
authors.lastname: Peereboom
authors.forename: R
authors.initials: R
authors.lastname: Tubbs
authors.forename: D
authors.initials: D
authors.lastname: McLain
authors.forename: G T
authors.initials: GT
authors.lastname: Budd
authors.forename: T
authors.initials: T
authors.lastname: Griffin
authors.forename: A
authors.initials: A
authors.lastname: Novick
authors.forename: T A
authors.initials: TA
authors.lastname: Hamilton
authors.forename: J
authors.initials: J
authors.lastname: Finke
mesh_terms: D000818:Animals; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D019743:Chemokines, CXC / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D007371:Interferon-gamma / Q000096:biosynthesis*; D018664:Interleukin-12 / Q000494:pharmacology*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D051379:Mice; D012333:RNA, Messenger / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: C080810:CXCL9 protein, human; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D019743:Chemokines, CXC; D036341:Intercellular Signaling Peptides and Proteins; D012333:RNA, Messenger; D011994:Recombinant Proteins; D018664:Interleukin-12; D007371:Interferon-gamma